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Development of the resistance is the major problem in cancer therapy. Docetaxel is a taxol alkaloid that 
is frequently used in metastatic breast cancer. However, resistance often limits the usefulness of this 
drug in many breast cancer patients. Manipulation of resistant cells to re-sensitize to the therapeutic 
effect of docetaxel is current strategy to overcome this problem. Here, we have introduced ‘Iturin A’ 
as a potent chemosensitizer in docetaxel resistant breast cancer cells. Combination of Iturin A and 
docetaxel treatment significantly hampered the proliferation of docetaxel resistant MDA-MB-231 
and MDA-MB-468 breast cancer cells. Cell cycle analysis also showed massive amount of apoptotic 
population (Sub G0/G1) in combination therapy. A number of apoptotic and anti-apoptotic proteins 
were significantly altered in dual drug treated groups. Caspase 3 dependent cell death was observed in 
dual treatment. Molecular mechanism study showed that over-expression of Akt and its downstream 
signaling pathway was associated with docetaxel resistance. Iturin A significantly reduced Akt signaling 
pathway in resistant cells. This mechanistic action might be the reason behind the chemo-sensitization 
effect of Iturin A in docetaxel resistant breast cancer cells. In conclusion, Iturin A resensitized the 
resistant breast cancer cells to docetaxel therapy by inhibiting Akt activity.
Breast cancer is the most frequently disease diagnosed worldwide. Therapeutic strategy depends on expression 
of a number of receptors including estrogen receptor, progesterone receptor and human growth factor receptor 
2. The clinical benefits of hormonal therapy, chemotherapy and immunotherapy are highly co-related with the 
expression of above receptors.
Docetaxel is a FDA approved semi-synthetic taxol alkaloid molecule. It is used as 1st line chemotherapeutic 
agent in metastatic breast cancer therapy. It displays cell cycle arrest and apoptosis in cancer cells by stabilizing 
and preventing depolymerization of microtubules. However, development of docetaxel resistance is major clin-
ical problem in different cancers including breast cancer patients1. Activation of a number of survival signaling 
pathways has been reported to promote resistant phenotype in cancer cells in response to docetaxel treatment. 
Other factors are activation of P-glycoprotein, inhibition of apoptotic mechanism, metabolic alteration, changes 
in microtubule structure and binding efficiency of docetaxel to the microtubules2. P-glycoprotein or multidrug 
resistant protein 1 (MDR 1) is the major contributing factor for chemotherapeutic insensitivity.
Akt signaling plays a critical role in cancer associated phenomena including tumorigenesis, proliferation, 
invasion, metastasis and angiogenesis. Activated Akt pathway is also responsible for development of resistance 
in cancer cells to various chemotherapeutics drugs3–6. Moreover, Akt has been found to have positive co-relation 
with P-glycoprotein that is involved in drug efflux and multidrug resistance in cancer cells7. In previous report, 
Akt was found to be up-regulated in docetaxel resistant cancer cells8. So, Akt inhibition can lead to develop-
ment of new therapeutics strategy to overcome chemoresistance. Some earlier report showed that some specific 
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Akt inhibitors can resensitize cancer cells to various chemotherapeutics agents9,10. In breast cancer model Akt 
is the critical mediator for insensitivity of chemotherapeutic agents. High level of Akt in breast cancer cells was 
co-related with enhanced resistance to chemotherapeutic agents and tumor with more Akt expression are suscep-
tible to recurrence and relapse11.
Microbial lipopeptides represent a unique class of pharmacologically active molecules12. In pharmaceuti-
cal application, lipopeptides particularly daptomycin, caspofungin and viscosin are reported to have potential 
anti-bacterial, anti-fungal and anti-viral activities13. Recently, it was found that lipopeptides are also effective 
in multidrug resistant bacteria including methicillin-resistant Staphylococcus aureus and penicillin resistant 
Streptococcus pneumonia, gram negative bacteria and extremely drug resistant clinically isolates13–15. In our pre-
vious findings we isolated ‘Iturin A’ from marine bacteria Bacillus megaterium and tested its anti-tumor efficacy 
in various in vitro and in vivo models. It displayed anti-cancer efficacy by inhibiting Akt signaling pathway16,17. 
However, the effect of Iturin A on resistance cancer cells was not previously documented. In the current investiga-
tion, we systematically tested the potential efficacy of Iturin A in docetaxel resistant cancer cells. Our hypothesis 
was that due to Akt inhibitory effect, Iturin A could reverse the insensitivity of docetaxel resistant breast cancer 
cells.
Results
Generation and establishment of docetaxel resistant cells. Sensitive MDA-MB-231 and 
MDA-MB-468 breast cancer cells were treated with gradual increasing dose of docetaxel to establish docetaxel 
resistant cell lines. Initially cells were treated with 20 nM of docetaxel and further cells were treated with increas-
ing dose of docetaxel and subsequently passaged for one year (Fig. 1A).
Morphological features of sensitive and resistant cells. Prominent morphological changes were 
observed due to development of docetaxel resistance in breast cancer cells. The comparative morphology of 
MDA-MB-231, MDA-MB-468, MDA-MB-231R and MDA-MB-468R cells was shown in Fig. 1B and C. The mor-
phology of sensitive cells was small size, well organized nucleus, and absence of vesicles. On the other hand resist-
ant breast cancer cells displayed large cellular size, irregular shape, multiple nucleuses and increasing number of 
large vesicles.
Cytoskeleton rearrangement in resensitized breast cancer cells. Cytoskeleton rearrangement was 
determined by rhodamine phalloidin staining. Sensitive cells displayed a well-organized actin filament without 
stress fiber. Docetaxel resistant cells showed parallel actin filaments with stress fiber. Treatment with Iturin A and 
docetaxel caused prominent actin reorganization, cellular shrinkage and collapse of actin filaments in resistant 
breast cancer cell lines (Fig. 1D and E).
Comparative protein expression in sensitive and resistant breast cancer cells. We performed 
western blot analysis to check the level of different proteins associated with resistant development process. At first 
Akt level was checked (Fig. 1F and G). The expression of P-Akt was observed to be significantly high in resistant 
MDA-MB-231R and MDA-MB-468R cells compared to sensitive cells. Total Akt level was found almost equal in 
both sensitive and resistant cells.
Determination of IC50 doses in breast cancer cells. The sensitivity of docetaxel in sensitive and resist-
ant breast cancer cells was determined by conventional MTT assay (Fig. 2). The IC50 values of docetaxel in sensi-
tive and resistant cells were presented in Fig. 2A and B. The IC50 value of Iturin A and docetaxel in resistant cells 
was also reported in Fig. 2F. MTT assay was performed to determine IC50 dose of docetaxel in presence of Iturin 
A (Fig. 2E) in resistant cells. Further, MTT assay was performed in resistant cells treated with different dose of 
Iturin A in absence or presence of 50 nM dose of docetaxel (Fig. 2C and D). In this combination, the IC50 values 
of Iturin A were 4.0 µM and 5.6 µM in MDA-MB-231R and MDA-MB-468R cells (Fig. 2F). Based on the result 
from MTT assay, we selected the dose of Iturin A and docetaxel for further experiments.
Iturin A potentiated docetaxel mediated toxicity. Resistant cells were treated with Iturin A and/or 
docetaxel for 48 h and microscopic observation was recorded by phase contrast microscope (Fig. 3A and B). 
Docetaxel caused very few cellular deaths in both resistant cells. Iturin A also caused slight cellular death. 
Interestingly, huge number of dead cells (Characterized by loss of lamellipodia/filopodia, cell rounding and 
shrinkage of cells and detachment of cells) was observed in combination treatment of docetaxel and Iturin A 
groups.
Quantification of apoptotic cell death by flow cytometry. Resistant MDA-MB-231R and MDA-MB-
468R cells were treated with Iturin A and/or docetaxel. The combination of these two agent caused huge apoptotic 
cellular death in resistant cells. Single treatment with Iturin A or docetaxel displayed slight apoptotic effect in both 
cell lines (Fig. 3C and D).
Detection of early apoptosis in resistant breast cancer cells. Externalization of phosphatidylserine 
was detected in treated resistant breast cancer cells. This biochemical phenomenon is associated with early apop-
totic event. Our study showed that few annexin positive cells (green florescent) were present in Iturin A treated 
group. In docetaxel treated group less number of annexin positive cells was present. However in combined treated 
group, significantly high numbers of annexin positive cells were observed indicating elevated apoptotic induction 
due to resensitization effect of Iturin A (Fig. 4A and B).
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Iturin A and docetaxel significantly suppressed the colony formation. Cell reproductive death 
was detected by conventional colony formation assay. A large number of colony was observed in control cells. 
Iturin A treatment showed slight inhibition of number of colony formation. Further, docetaxel treatment had no 
significant effect in colony formation. Significantly less number of colonies was observed in combined treated 
MDA-MB-231R and MDA-MB-468R (Fig. 4C and D).
Western blot experiment displayed modulation of apoptosis regulatory proteins. Resistant 
breast cancer cells were treated with Iturin A, docetaxel or combination. Expression of various proteins was 
observed. Expression of anti-apoptotic proteins (Bcl-2 and Bcl-xL) were significantly down regulated in combi-
nation treated group. Apoptotic protein, Bax was significantly up-regulated in combined treated group in both 
MDA-MB-231R and MDA-MB-468R cells. Bcl-2/Bax ratio was significantly reduced in dual drug treated groups. 
Figure 1. (A) Graphical representation of generation of resistant breast cancer cells from sensitive breast 
cancer cells. Docetaxel sensitive MDA-MB-231 and MDA-MB-468 cells were cultured and treated with low 
dose of docetaxel and then dose was increased gradually to generate resistant breast cancer cells. (B and C) 
Phase contrast images of sensitive and resistant breast cancer cells. Scale bar represents 100 µm. (D and E) Actin 
organization of sensitive and resistant breast cancer cells was shown in figure. Sensitive cells were small in size, 
normal actin organization. The actin organization of resistant cells was elongated and parallel orientation of 
actin filaments. (F and G) Akt expression in sensitive and resistant breast cancer cells (Blots were cropped and 
presented). The significance level was represented by *P < 0.05, **P < 0.01, ***P < 0.001.
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Caspase 3 is the critical mediator of apoptosis phenomenon. In our experiment cleavage of caspase 3 was promi-
nent in resensitized cells indicating huge cell death in the combination group (Fig. 5A and B).
Inhibition of Akt signaling resensitized the resistant cells to docetaxel. Next we evaluated expres-
sion of P-Akt and its downstream signaling. Iturin A slightly inhibited P-Akt expression and docetaxel treatment 
Figure 2. MTT assay of sensitive and resistant breast cancer cells treated with various treatment strategies. 
(A) Sensitive MDA-MB-231 and MDA-MB-468 cells were treated with various doses of docetaxel for 48 h and 
MTT assay was performed. (B) MTT assay was performed to determine the IC50 values of docetaxel in resistant 
MDA-MB-231R and MDA-MB-468R cells. (C) MDA-MB-231R cells were treated with Iturin A or combination 
of Iturin A along with 50 nM docetaxel for 48 h. The IC50 values Iturin A were determined. (D) MDA-MB-231R 
cells were treated with Iturin A or combination of Iturin A along with 50 nM docetaxel. The IC50 values Iturin 
A were determined. (E) MTT assay to determine IC50 of Docetaxel in presence of Iturin A (1/4th IC50 dose of 
Iturin A) in resistant cells. (F) IC50 values of Docetaxel and Iturin A were shown in various treatment strategies.
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Figure 3. (A and B) Phase contrast images resistant breast cancer cells treated with docetaxel and/or Iturin A 
for 48 h. Apoptotic cells were counted in each group. Resistant MDA-MB-231R and MDA-MB-468R cells were 
treated with docetaxel and/or Iturin A for 48 h. Bar graph represented arbitrary number apoptotic dead cells in 
MDA-MB-231R and MDA-MB-468R. (C and D) Flow cytometric analysis of resistant breast cancer cells treated 
with docetaxel and/or Iturin A for 48 h to determine DNA content based quantitative apoptotic effect. Bar graph 
represented apoptotic population (Sub G0) cells in MDA-MB-231R and MDA-MB-468R. In all experiments, 
cells were treated with Iturin A (4 µM for MDA-MB-231R and 5.6 µM for MDA-MB-468R) and docetaxel 
(50 nM in both resistant cells) in specific doses. The significance level was represented by *P < 0.05, **P < 0.01, 
***P < 0.001.
Figure 4. (A and B) Annexin-FITC/PI staining of resistant breast cancer cells treated with docetaxel and/
or Iturin A for 48 h for detection of early apoptotic effect. Bar graph represented arbitrary number early 
apoptotic MDA-MB-231R and MDA-MB-468R cells. (C and D) Colony formation assay of resistant breast 
cancer cells MDA-MB-231R and MDA-MB-468R treated with docetaxel and/or Iturin A for 48 h to analyze cell 
reproductive death. Bar graph represented number of colony in different groups of MDA-MB-231R and MDA-
MB-468R. In all experiments, cells were treated with Iturin A (4 µM for MDA-MB-231R and 5.6 µM for MDA-
MB-468R) and docetaxel (50 nM in both resistant cells) in specific doses. The significance level was represented 
by *P < 0.05, **P < 0.01, ***P < 0.001.
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fails to inhibit P-Akt in resistant cells. Combination of Iturin A and docetaxel treatment significantly suppressed 
P-Akt expression. Expression level of total Akt protein was not significantly change among various groups. GSK3β 
is downstream protein of Akt signaling. We also tested phosphorylation status of GSK3β. Like P-Akt, similar kind 
of results was observed in P-GSK3β (Fig. 6A and B).
Discussions
The menace of chemoresistance is the potential drawback during the clinical management of multiple cancers 
including breast cancer. During the early stage of treatment, chemotherapeutic drugs may be effective but grad-
ually they display poor clinical response due to acquired resistance of cancer cells18. Some chemotherapeutic 
drugs are also less effective to cancer owing to inherent resistance of cancer cells19. Numerous molecular drivers 
in cancer cells were discovered previously expanding the knowledge domain of chemoresistance20. These findings 
enable the scientist to discover novel therapeutic approaches to overcome the chemoresistance. Docetaxel is cur-
rently drug of choice for treatment of locally advanced and metastatic breast cancer21. In addition, docetaxel is the 
drug of choices for triple negative breast cancer. So, in our study we selected highly invasive and triple negative 
breast cancer cells MDA-MB-231 and MDA-MB-468. Many cancer patients are unresponsive or less responsive 
to docetaxel therapy. Resensitization of resistant cancer cells with other agent to chemotherapeutic drug is estab-
lished strategy. In this current investigation, we evaluated the effect of Iturin A in docetaxel resistant cancer cells.
Initially, we generated the resistant cells from sensitive cells (Fig. 1A). Characteristics cellular arrangement 
was observed in resistant cells by phase contrast (Fig. 1B and C) and rhodamine phalloidin staining (Fig. 1D 
and E). Large and multiple number of vesicles inside the resistant cells were observed. In addition to this, actin 
reorganization, increased cellular size and presence of multinucleations were also observed in docetaxel resistant 
cells. These altered morphological features were previously reported in resistant cancer cells including multiple 
vesicles, large and multi-neucleated cells22,23. Presence of large number of vesicles may prevent the cells from the 
lethal effects of cytotoxic drugs by employing different mechanisms24,25. Akt has prominent role in tumorigenesis, 
cell survival, radioresistance and chemoresistance3,26 in multiple cancers. Expression of P-Akt was evaluated in 
sensitive and resistant cells. Our result showed that P-Akt expression was elevated in resistant MDA-MB-231R 
and MDA-MB-468R cells compare to sensitive cells (Fig. 1F and G). Inhibition of Akt is accepted strategy to 
overcome resistance in cancer cell27. The sensitivity of Iturin A was tested in resistant cells by MTT assay (Fig. 2). 
The IC50 value of docetaxel was determined in sensitive as well as resistant cells (Fig. 2). In resensitization assay, 
Figure 5. Western blot analysis of apoptosis related proteins. (A) Western blot analysis of MDA-MB-231R and 
MDA-MB-468R treated with docetaxel and/or Iturin A for 48 h (Blots were cropped and presented). (B) Bar 
graph represented densitometric plot of protein expression in various groups in MDA-MB-231R and MDA-
MB-468R. The significance level was represented by *P < 0.05, **P < 0.01, ***P < 0.001.
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50 nM docetaxel showed 50% cellular proliferation in presence of 4.0 and 5.6 µM of Iturin A in MDA-MB-231R 
and MDA-MB-468R cells. These finding clearly indicated the reversal effect of Iturin A in MDA-MB-231R and 
MDA-MB-468R cells (Fig. 2). Phase contrast microscopy was performed to check effect of Iturin A on MDA-MB-
231R and MDA-MB-468R cells resensitization. Single treatment with Iturin A or docetaxel displayed very less 
apoptotic effect on MDA-MB-231R and MDA-MB-468R cells. However, the combination of these two agents 
showed significant level of apoptosis in resistant cells (Fig. 3A and B). Next, flow cytometry based cell cycle 
analysis was performed. Similar with previous result, individual treatment showed very less apoptotic population 
and combined treatment caused drastic apoptotic population in resistant cells (Fig. 3C and D). Externalization of 
phosphatidylserine is the critical marker for detection of early apoptotic events28. Here annexin/PI staining was 
performed to detect early apoptosis. Enormous numbers of early apoptotic cells (green florescent) were observed 
in combination treatment compare to individual treated group (Fig. 4A and B). Next we have performed colony 
forming capacity of resistant cells treated with Iturin A or docetaxel. Generally, colony formation assay deter-
mines cell reproductive death of cancer cells by anti-cancer agents measuring the effectiveness of chemotherapy29. 
Combined treatment displayed very low number of colonies reflecting potent cytotoxic action of this combina-
tion on reproductive ability of cancer cells (Fig. 4C and D). Apoptosis analysis at protein level was checked by 
western blot analysis. Bcl-2 protein is the critical component of tumor associated apoptosis event. Overexpression 
of Bcl-2 protein can promote proliferation tumorigenesis and inhibition of apoptosis in multiple cancers. In our 
findings, Iturin A and docetaxel potently suppress Bcl-2 expression in combination (Fig. 5A and B). Another 
apoptosis related important protein is Bax. Bax down regulation play a critical role in cancer progression30. 
Apoptosis inducing chemotherapeutic drugs often up-regulate Bax expression in cancer cells31. In our study, sig-
nificant Bax up-regulation was noticed in resensitized cells treated with Iturin A in combination with docetaxel 
(Fig. 5). Caspase activation is the necessary part of biological process of apoptosis32. Here caspase 3 activations 
Figure 6. Western blot analysis of resistant cells. (A) Western blot analysis of MDA-MB-231R and MDA-
MB-468R treated with docetaxel and/or Iturin A for 48 h (Blots were cropped and presented). (B) Bar graph 
represented densitometric plot of protein expression in various groups in MDA-MB-231R and MDA-MB-468R. 
The significance level was represented by *P < 0.05, **P < 0.01, ***P < 0.001.
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were found prominent in combination therapy in resistant MDA-MB-231R and MDA-MB-468R cells (Fig. 5). 
Akt signaling pathway has been reported to promote cell survival, inhibition of apoptosis, resistance to multiple 
chemotherapeutic drugs like cisplatin, carboplatin, doxorubicin, 5-flurouracil, cyclophosphamide, paclitaxel and 
docetaxel4,33–38. Inhibition of Akt signaling can resensitize the cancer cells. Our study showed that inhibition 
of Akt by Iturin A treatment resensitized the resistant cells to docetaxel treatment. Expression of phospho Akt 
was reduced in Iturin A treated group. Docetaxel treatment was unable to inhibit P-Akt in MDA-MB-231R and 
MDA-MB-468R cells. However, drastic change of P-Akt expression was noticed in Iturin A along with docetaxel 
treated groups (Fig. 6). The downstream protein GSK3β is major Akt substrate. Phosphorylation state of GSK3β 
was also drastically downregulated in resensitized cells treated with Iturin A and docetaxel combination (Fig. 6).
Our findings offered a novel approach to overcome chemoresistance that is a major clinical problem in chemo-
therapy. Docetaxel treatment is the critical part of standard chemotherapeutic regimen of breast cancer therapy. 
However, insensitivity or resistance to docetaxel therapy is the challenging drawback for successful cancer manage-
ment. Akt is frequently over-expressed in resistant cell population. In our study, Iturin A inhibited Akt and restored 
the sensitivity of resistant MDA-MB-231R and MDA-MB-468R breast cancer cells to docetaxel therapy (Fig. 7).
Materials and Methods
Chemical reagents. Docetaxel was purchased from Sigma-Aldrich. Stock solution of docetaxel was pre-
pared in DMSO and stored in −20 °C. Further, working solution was prepared in incomplete DMEM medium. 
Iturin A was dissolved in mili Q water and pH was adjusted to 7.0. A number of antibodies were procured as 
following: Bcl-2, Bcl-XL, MCL-1, Bax and caspase-3, (Cell Signaling, Beverly, MA, USA). β-actin, mouse IgG 
and rabbit IgG (Sigma-Aldrich, St. Louis, MO, USA). Propidium iodide, ECL Kit, DAPI, RNase A, and MTT 
reagents were purchased from Sigma-Aldrich. DMEM medium and fetal bovine serum (FBS) was purchased 
from Invitrogen, USA.
Cell line and culture conditions. MDA-MB-231 and MDA-MB-468 breast cancer cells were purchased 
from National Centre for Cell Science, Pune, India. Cells were grown in T25 flask using DMEM complete 
medium. After 70% confluence cells were passaged regularly and kept in humidified 5% CO2 incubator. For each 
experiment cells were taken from T25 flask.
Generation of resistant cell lines. Docetaxel resistant MDA-MB-231 and MDA-MB-468 cells were gen-
erated from sensitive cell lines according to earlier reported method with some modifications39. Initially, sensitive 
MDA-MB-231 and MDA-MB-468 cells were treated with a sub-lethal dose of docetaxel (20 nM) for 48 hr. Then, 
docetaxel containing medium was discarded to remove dead floating cells and fresh medium was added for 72 
hr to recover the live cells. Cells were then passaged. Live cells were again treated with 40 nM docetaxel for 48 hr 
and after that cells were kept in fresh medium for 72 hr. In this way we increased the dose by 20 nM and ulti-
mately around 1000 nM docetaxel was used to treat the cells. At the end of one year time, cells became resistant 
(MDA-MB-231R and MDA-MB-468R). In these cells, MTT assay was performed to access drug sensitivity.
Figure 7. Proposed mechanism of action of Iturin A in inhibiting resistant cancer cells through suppressing 
Akt activity.
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MTT assay. Anti-proliferative effect was determined by colorimetric based MTT assay according to earlier 
reported method40. In brief, MDA-MB-231, MDA-MB-468, MDA-MB-231R and MDA-MB-468R cells were 
seeded in 96 well plates. After overnight incubation, cells were treated with different concentration of docetaxel 
for 48 h. After treatment, medium was discarded and MTT solution (1 mg/ml in incomplete DMEM medium) 
was added and cells were incubated for 5 h. After incubation MTT solution was discarded and DMSO was added 
in each wells.
Phase contrast microscopy. MDA-MB-231, MDA-MB-468, MDA-MB-231R and MDA-MB-468R cells 
were seeded in 30 mm Petri dish. The morphology of sensitive as well as resistant cells was captured by phase 
contrast microscopy41. In another set of experiment, MDA-MB-231R and MDA-MB-468R cells were seeded in 
30 mm Petri dish. After 70% confluence, cells were treated with Iturin A and/or docetaxel for 48 h. The dose 
of Iturin A was 4 µM and 5.6 µM Iturin A for MDA-MB-231R and MDA-MB-468R respectively. The dose of 
docetaxel was 50 nM for both resistant cell lines. After treatment, phase contrast images of treated resistant cells 
were captured by microscope. In next experiments, resistant cells were treated with above mentioned Iturin A 
and docetaxel.
Actin reorganization. Actin reorganization of resistant cells was visualized by rhodamine phalloidin/DAPI 
staining according to previously reported method41. Briefly, MDA-MB-231R and MDA-MB-468R cells were 
seeded on cover slips. After 70% confluence, cells were treated with Iturin A and/or docetaxel for 48 h. After treat-
ment, cells were washed, fixed and stained with rhodamine phalloidin. Florescent images of treated resistant cells 
were captured by Zeiss Observer Z1 microscope (Carl Zeiss, Germany) at 20 × magnifications.
Cell cycle analysis. Quantitative apoptotic effect was determined by DNA content based flow cytometric 
analysis according to earlier reported method42. MDA-MB-231R and MDA-MB-468R cells were seeded in 60 mm 
Petri dish. Cells were treated with Iturin A and/or docetaxel for 48 h in incomplete medium. After treatment, cells 
were harvested by trypsin treatment. Collected cells were fixed in 70% chilled ethanol for overnight. Then, cells 
were stained with propidium iodide mixed with RNAse. Cells were kept at 37 °C for 30 minutes. Samples were 
subjected to flow cytometric analysis.
Annexin/PI staining. Externalization of phosphatidylserin (Marker of early apoptosis) was checked by 
Annexin-FITC/PI staining in treated cells according to earlier reported method43. Briefly, MDA-MB-231R and 
MDA-MB-468R cells were seeded in 30 mm Petri dish. Cells were then treated with Iturin A and/or docetaxel 
for 48 h. After treatment, cells were harvested and cell suspension was stained using Annexin V-FITC apoptosis 
detection kit (sigma) according to manufacturer protocol. Cells were then placed on glass slides and florescent 
images were captured by Zeiss Observer Z1 microscope (Carl Zeiss, Germany) at 20 × magnifications.
Colony formation assay. Cellular reproductive growth of resistance cells were determined by colony for-
mation assay as earlier reported method29. Resistant cells were initially treated with Iturin A and/or docetaxel 
for 24 h. Cells were harvested and 1000 cells were seeded in six well plates. After 7 days, number of colony was 
counted in each group. Each colony contains greater than 50 cells.
Western blot analysis. Western blot analysis of MDA-MB-231, MDA-MB-468, MDA-MB-231R and 
MDA-MB-468R cells was performed to check Akt level according to earlier reported method44. In brief, 
MDA-MB-231, MDA-MB-468, MDA-MB-231R and MDA-MB-468R cells were seeded on 60 mm Petri plats. 
After 70% confluence cells were collected, washed with PBS and lysed with NP-40 lysis buffer. After lysis cell 
debris was separated by centrifuge and clear supernatants was collected in fresh tube. Concentration of pro-
tein was estimated by commercially available protein estimation kit. Samples were prepared by adding 6x dye 
and boiling. Equal amount of protein was loaded in each wells and subjected to SDS PAGE gel electrophoresis. 
Protein was transferred to nitrocellulose membrane. Detection of protein expression was evaluated after using 
primary and secondary antibodies. In another experimental setup, resistant cells were treated with Iturin A and/
or docetaxel. Western blot analysis was performed to evaluate a number of protein expressions.
Statistical analysis. All experiments were performed at least three times. Experimental values were pre-
sented as mean ± S.D. Graphpad Prism software was used to draw bar graphs. P value was calculated using stu-
dent’s t test. P value < 0.05 was considered statistically significant. P value was calculated in various experiments 
to compare significance among the various groups.
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